Deciphering the mechanisms of Yinlan Tiaozhi capsule in treating hyperlipidemia by combining network pharmacology, molecular docking and experimental verification

• Published in: Scientific reports Vol. 13; no. 1; p. 6424
• Main Authors: Xiao, Guanlin, Hu, Zixuan, Jia, Canchao, Yang, Minjuan, Li, Dongmei, Xu, Aili, Jiang, Jieyi, Chen, Zhao, Li, Yangxue, Li, Sumei, Chen, Weitao, Zhang, Jingnian, Bi, Xiaoli
• Format: Journal Article
• Language: English
• Published: England Nature Publishing Group 19.04.2023; Nature Publishing Group UK; Nature Portfolio
• Subjects: Acids; Angiogenesis; Animals; Drugs, Chinese Herbal - pharmacology; Drugs, Chinese Herbal - therapeutic use; Ferulic acid; Flavonoids; Gene expression; Hyperlipidemia; Hyperlipidemias - drug therapy; Inflammation; Interleukin 6; Lactones; Molecular Docking Simulation; Naringenin; Network Pharmacology; Organic acids; Pharmacology; RNA, Messenger; Saponins; Tandem Mass Spectrometry; Therapeutic targets
• DOI: 10.1038/s41598-023-33673-3
• ISSN: 2045-2322

Yinlan Tiaozhi capsule (YLTZC) has been widely used to treat hyperlipidemia (HLP). However, its material basis and underlying pharmacological effects remain unclean. The current study aimed to explore the mechanisms involved in the treatment of YLTZC on HLP based on network pharmacology, molecular docking, and experimental verification. Firstly, UPLC-Q-TOF-MS/MS was used to comprehensively analyze and identify the chemical constituents in YLTZC. A total of 66 compounds, mainly including flavonoids, saponins, coumarins, lactones, organic acids, and limonin were characterized and classified. Simultaneously, the mass fragmentation pattern of different types of representative compounds was further explored. By network pharmacology analysis, naringenin and ferulic acid may be the core constituents. The 52 potential targets of YLTZC, including ALB, IL-6, TNF, and VEGFA, were considered potential therapeutic targets. Molecular docking results showed that the core active constituents of YLTZC (naringenin and ferulic acid) have a strong affinity with the core targets of HLP. Lastly, animal experiments confirmed that naringenin and ferulic acid significantly upregulated the mRNA expression of ALB and downregulated the mRNA expression of IL-6, TNF, and VEGFA. In sum, the constituents of YLTZC, such as naringenin and ferulic acid, might treat HLP by regulating the mechanism of angiogenesis and inhibiting inflammatory responses. Furthermore, our data fills the gap in the material basis of YLTZC.